FFO
PLRX icon

Fortitude Family Office’s Pliant Therapeutics PLRX Stock Holding History

Fortitude Family Office’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,278
Closed -$1.56K – 2031
2025
Q4 		$1.56K Hold
1,278
– – ﹤0.01% 1281
2025
Q3 		$1.89K Buy
+1,278
New +$1.95K ﹤0.01% 1243

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Fortitude Family Office's PLRX Position: Q1 2026 in Review

Fortitude Family Office sold out of Pliant Therapeutics (PLRX) in Q1 2026, closing a stake of 1,278 shares — an estimated $1.56K sold.

Fortitude Family Office first reported a position in PLRX in Q3 2025 and held it in 2 quarters. The position peaked at $1.89K in Q3 2025. 91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

  • Fortitude Family Office reported no remaining Pliant Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fortitude Family Office sold 1,278 Pliant Therapeutics shares in Q1 2026, an estimated $1.56K.
  • Fortitude Family Office first reported a position in Pliant Therapeutics in Q3 2025 and held it in 2 quarters.
  • Fortitude Family Office's Pliant Therapeutics position peaked at $1.89K in Q3 2025.
  • 91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.